[Secukinumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V (new scientific findings)]


Original post, click here

Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung. [Secukinumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V (new scientific findings)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 515. 2017

Indexing Status

Subject indexing assigned by CRD

MeSH

Antibodies, Monoclonal; Humans; Psoriasis

Language Published

German

Country of organisation

Germany

English summary

There is no English language summary available.

Address for correspondence

IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 – 35685 – 0, Fax: +49 (0) 221 – 35685 – 1 Email: berichte@iqwig.de

AccessionNumber

32017000261

Date abstract record published

13/06/2017